Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG00011 · 1 trial · 1 indication
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| BG00011 | EXPERIMENTAL | Participants will receive 8 consecutive weekly doses of BG00011 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 8 consecutive weekly doses of placebo. |
| Name | Type | Description |
|---|---|---|
| BG00011 | DRUG | BG00011 will be administered at varying doses via subcutaneous (SC) injection |
| Placebo | DRUG | Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections. |
Key Inclusion Criteria: 1. Clinical features consistent with IPF prior to screening (based on the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) consensus criteria for the diagnosis of IPF). 2. Forced ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
BG00011 is an investigational small molecule being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The specific molecular target of BG00011 is not disclosed in the available information. The drug is being studied for its potential effects in patients with Idiopathic Pulmonary Fibrosis, but its precise mechanism of action has not been publicly detailed.
BG00011 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Idiopathic Pulmonary Fibrosis.
BG00011 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received approval from regulatory agencies. The drug is being studied for the treatment of Idiopathic Pulmonary Fibrosis, and its clinical program is ongoing.
BG00011 has been studied in one completed Phase 2 clinical trial with the identifier NCT01371305. This trial, titled 'STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)', enrolled 41 participants in the United States. The study was randomized, double-blind, and placebo-controlled.
Yes, BG00011 is also known as STX-100. The clinical trial NCT01371305, which evaluated the drug in patients with Idiopathic Pulmonary Fibrosis, used the name STX-100 in its title. Both names refer to the same investigational compound being developed by Biogen.